MedTrace Logo

Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study

NCT02756468 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-04-29

No results posted yet for this study

Summary

Background. Pancreatic cancer surgery is associated with very high risk of postoperative morbidity and mortality. Anastomotic leak (AL) is one of the worst complications associated with relevant short and long-term sequelae. Procalcitonin (PCT) is a biomarker used to monitor bacterial infections and guide antibiotic therapy and has been shown to have better predictive value of AL after colorectal surgery than C-reactive protein (CRP) and white blood cell count (WBC).

Purpose. The investigators designed a monocentric pilot study to test if PCT might be a sensitive and reliable marker of AL after pancreatic surgery

Conditions

Interventions

OTHER

pts operated for pancreatic cancer

measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756468 on ClinicalTrials.gov